Occurrence and accuracy of a register-based diagnosis of pediatric bipolar disorder: A nationwide cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Objective: To investigate the accuracy of a diagnosis of pediatric bipolar disorder in the Danish National Register compared to the patient charts. Second, we reported on the occurrence of a diagnosis of pediatric bipolar disorder during the study period. Methods: All persons appearing in the Danish nationwide registers between 1995 and 2014 with an incident ICD-10 diagnosis of single hypomanic/manic episode or a diagnosis of bipolar disorder (summarized as bipolar disorder [BD]) before turning 18 years were identified (n = 521) and a random sample (n = 131) hereof was selected for chart review. Each chart was reviewed by two independent Schedules for Clinical Assessment in Neuropsychiatry (SCAN) certified raters to assess whether symptoms documented in the chart were consistent with a formal diagnosis of BD according to the ICD-10 criteria or not. Results: The formal diagnostic criteria for BD according to the ICD-10 were fulfilled in 48 charts (45.3%, 95% CI: [36.1%, 54.8%]) out of 106 reviewable charts, age at index = 16.4 ± 1.6 (range = 9.1–18.3) years. Cohen’s Kappa ranged from 94.4% to 100%. The estimate of a lifetime prevalence up till the current age for bipolar disorder for those of aged 5–18 years, was 0.019% in 2014. Conclusion: Less than half of the register-based pediatric BD diagnoses were confirmed by chart review, which was lower than expected. The occurrence of a register diagnosis of pediatric BD was relatively low.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Australian and New Zealand Journal of Psychiatry |
| Vol/bind | 55 |
| Udgave nummer | 11 |
| Sider (fra-til) | 1101-1108 |
| ISSN | 0004-8674 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: M.R.-D. has reported no biomedical financial interests or potential conflicts of interest. A.K.B. has reported no biomedical financial interests or potential conflicts of interest. M.F.L. has received speaking fees from Lundbeck. R.E.N has received research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials, received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals, Teva and Eli Lilly and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda and Medivir. C.U.C. has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. R.W.L. has within the preceding 3 years served an advisory board of Janssen-Cilag and SAGE and has received speaker honorarium from Astra-Zeneca, Janssen-Cilag, Servier and Lundbeck.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The study was funded by the Unit for Psychiatric Research, Psychiatry, Aalborg University Hospital, Aalborg, Denmark and Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
Publisher Copyright:
© The Royal Australian and New Zealand College of Psychiatrists 2021.
ID: 269620962